Clinical trials: Rosuvastatin
End-stage Kidney Disease, Diabetes Mellitus
Vascular Protective Effect of Rosuvastatin in Arteriovenous Fistula
Background Arteriovenous (AV) fistula is the most common vascular access for long-term hemodialysis in the end-stage renal disease (ESRD) patients. About 25% of these patients are diabetes mellitus.
- Conditions
- End-stage Kidney Disease, Diabetes Mellitus, Arteriovenous Fistula
- Trial name
- NCT01863914
- Testing
- Rosuvastatin
- Where
- Taiwan
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Cheng-Kung University Hospital
Preeclampsia
Effect of Rosuvastatin on the Clinical Features of Preeclampsia
The primary outcome will be the effect of rosuvastatin on the resolution of biochemical features associated with severe PE (↑CRP and IL6). .
- Trial name
- NCT04303806
- Testing
- rosuvastatin
- Volunteers
- 80 people
- Sponsor
- Assiut University
Sexual Dysfunction
Statin Lowering Testosterone and Sexual Function
Statins may decrease serum testosterone levels via decreasing cholesterol. This longitudinal study detected the effects of rosuvastatin on free testosterone levels and sexual function in men with type 2 diabetes.
- Trial name
- NCT02612714
- Testing
- Rosuvastatin
- Where
- Taiwan
- Volunteers
- 151 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Hypertension, Hyperlipidemia
Clinical Trial to Compare the Safety and Pharmacokinetics of YHP1604 in Comparison to the Co-administration of Telmisartan/Amlodipine and Rosuvastatin
This is a phase 1, open label, single-dose, crossover study to investigate the pharmacokinetics of YHP1604 in comparison to the co-administration of telmisartan/amlodipine and rosuvastatin in healthy male volunteers Hypothesis…
- Trial name
- NCT03116516
- Testing
- Temisartan/Amlodipine+Rosuvastatin, YHP1604
- Where
- South Korea
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Yuhan Corporation
Hypertriglyceridemia
Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)
The primary objective is to determine the efficacy of AMR101 (ethyl icosapentate) compared to placebo in lowering high fasting triglyceride levels in patients with high risk for cardiovascular disease and fasting triglyceride…
- Trial name
- ANCHOR (NCT01047501)
- Testing
- AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day
- Where
- 80 sites in United States
- Volunteers
- 702 people
- Sponsor
- Amarin Pharma Inc.
Familial Hypercholesterolemia
A Study to Determine the Safety, Tolerability, and Efficacy of SHR-1209 in Patients With Familial Hypercholesterolemia
The study is being conducted to evaluate the efficacy, safety and tolerability of SHR-1209 in subjects with familial hypercholesterolemia.
- Trial name
- NCT04455581
- Testing
- SHR-1209
- Volunteers
- 8 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Healthy
Investigation of Pharmacokinetic Interaction Between Rosuvastatin and Olmesartan in Healthy Male Volunteers
This study investigates pharmacokinetics and drug-drug interaction between Rosuvastatin and Olmesartan in healthy male volunteers
- Trial name
- NCT01831479
- Testing
- Rosuvastatin, Olmesartan, Rosuvastatin and olmesartan
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Severance Hospital
Drug Interactions
Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male Subjects
This is a Phase 1, open-label, fixed-sequence, 2-part DDI study. Subjects will participate in only 1 study part.
- Trial name
- NCT05657613
- Testing
- CYP450 Cocktail and Transporter Substrates with Pacritinib, Part 2 -Group A Bosentan 125 mg (CYP450 3A4 inducer) with Pacritinib, Part 2 Group B - Fluconazole (CYP450 3A4 inhibitor) with Pacritinib
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- CTI BioPharma
Endometriosis, Uterine Fibroids
A Phase 1 Clinical Study to Evaluate the Effects of SHR7280 on the Pharmacokinetics of Midazolam, S-warfarin, Omeprazole, Digoxin, and Rosuvastatin in Healthy Subjects
The purpose of this study is to evaluate the effects of SHR7280 on the pharmacokinetics of midazolam, S-warfarin, omeprazole, digoxin and rosuvastatin in healthy subjects.
- Conditions
- Endometriosis, Uterine Fibroids, Assisted Reproduction
- Trial name
- NCT06949124
- Testing
- SHR7280 Tablets
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Primary Hypercholesterolemia, Combined Hyperlipidemia
Study to Evaluate the Bioequivalence of "Crecheck Tablet 2.5 mg (Rosuvastatin Calcium)" and "Crestor Tablet 5 mg (Rosuvastatin Calcium)" in Healthy Adult Subjects
This clinical trial is an open, randomized, 2-group, 2-period, fasting, single-dose, crossover study to evaluate the bioequivalence of "Crecheck Tablet 2.5 mg (Rosuvastatin Calcium)" of Hanlim Pharm. Co., Ltd.
- Trial name
- NCT06475872
- Testing
- Crecheck Tablet 2.5 mg, Crestor Tablet 5 mg
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Hanlim Pharm. Co., Ltd.
Peripheral Artery Disease, Polyvascular Disease
Randomized Comparison of Efficacy and Safety of High-intensity Rosuvastatin/Ezetimibe Combination Versus Treat-to-target Rosuvastatin Monotherapy for Patients With Peripheral Artery or Polyvascular Disease (CARE-PVD Trial)
Patients with atherosclerotic peripheral artery disease often have combined coronary artery disease or cerebral artery disease and show high rates of cardiovascular mortality and morbidities.
- Trial name
- NCT06231966
- Testing
- Combination therapy of high-intensity dose rosuvastatin and ezetimibe, Rosuvastatin monotherapy for treat-to-target
- Where
- South Korea
- Volunteers
- 2,462 people
- Sponsor
- Yonsei University
Hypercholesterolemia, Hyperlipidemias
Ezetimibe-Rosuvastatin Evaluation Study
Evaluation of the efficacy of the stable ezetimibe-rosuvastatin combination in patients with primary hypercholesterolemia in achieving the target plasma LCL-C level.
- Conditions
- Hypercholesterolemia, Hyperlipidemias, Combinations of Drugs; Dependence
- Trial name
- ZEUS (NCT03947866)
- Where
- Greece
- Volunteers
- 600 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Hypercholesterolemia
Tolerability and Lipid Lowering Effect of Weekly/Biweekly Crestor in Statin Intolerant Patients Treated With Zetia
Recently, research studies have shown that patients who have had trouble taking statins every day, are able to take statins if they take them only once or twice a week.
- Trial name
- NCT00972829
- Testing
- Rosuvastatin, Ezetimibe
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Bronx VA Medical Center
Primary Hypercholesterolemia, Hypertension
To Evaluate the Efficacy and Safety of Co-administrated Ezetimibe/Rosuvastatin and Telmisartan in Patients With Essential Hypertension and Primary Hypercholesterolemia
This study is a multicenter, Randomized, double-blind, acitve-controlled, Phase 3 Clinical Trial in 8 weeks for screening, twice Investigational product administer, Follow up visit.
- Trial name
- NCT04659070
- Testing
- Experimental : Ezetimibe / Rosuvastatin + Telmisartan, Active comparator1 : Ezetimibe / Rosuvastatin, Active comparator2 : Telmisartan
- Where
- South Korea
- Volunteers
- 156 people
- Sponsor
- Hanlim Pharm. Co., Ltd.
Hypercholesterolemia
Genome-wide Analysis of Lipid-lowering Efficacy and Drug Level of Simvastatin and Rosuvastatin
This study will perform a genome-wide association study (GWAS) of the lipid responses to rosuvastatin and simvastatin and plasma concentrations of these two statins in a homogeneous group of Han Chinese patients.
- Trial name
- NCT04921657
- Testing
- Rosuvastatin 10mg
- Where
- Hong Kong
- Volunteers
- 362 people
- Sponsor
- Chinese University of Hong Kong
Prostate Cancer, Cardiovascular Disease
A Study for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients
RADICAL PC1 is a prospective cohort study of men with a new diagnosis of prostate cancer. RADICAL PC2 is a randomized, controlled trial of a systematic approach to modifying cardiovascular and lifestyle risk factors in men with a…
- Trial name
- RADICALPC (NCT03127631)
- Testing
- Nutrition, Exercise, Smoking cessation
- Where
- 61 sites in United States, Australia and 7 more
- Volunteers
- 5,000 people
- Sponsor
- McMaster University
HIV Infections, Drug Interactions
Drug-drug Interactions Between Antiretroviral Drugs and Cardiovascular Drugs in Elderly Patients
Ageing is characterized by physiological changes, which can impact drug pharmacokinetics and thereby cause drug-drug interactions.
- Conditions
- HIV Infections, Drug Interactions, Cardiovascular Diseases
- Trial name
- NCT03515772
- Testing
- Co-administration of darunavir with a cardiovascular drug
- Where
- 2 sites in Switzerland
- Volunteers
- 21 people
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Bioequivalence
Bioequivalence Study of Rosuvastatin in Healthy Volunteers Under Fasting Condition
The present study is conducted to evaluate and compare the relative bioavailability for Rosuvastatin in two different products containing 10 mg film coated tablet after single oral administration.
- Trial name
- NCT05197517
- Testing
- Rosuvastatin 10 mg
- Where
- Egypt
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Rania Mahmoud Mohamed
ASCVD, Impaired Fasting Glucose
High-Dose Statin Combined With Telmisartan vs Amlodipine on Glucose Metabolism in ASCVD Patients With IFG and Hypertension
This study will evaluate the effect of high-dose rosuvastatin combined with telmisartan or amlodipine on glucose metabolism in ASCVD patients with impaired fasting glucose and hypertension.
- Conditions
- ASCVD, Impaired Fasting Glucose, Hypertension
- Trial name
- NCT03474562
- Testing
- Duowell®, Monorova® + Amlopin®
- Where
- 4 sites in South Korea
- Volunteers
- 100 people
- Sponsor
- Yuhan Corporation
Hypercholesterolemia
Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)
Alirocumab (SAR236553/REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9).
- Trial name
- NCT01507831
- Testing
- Alirocumab, Lipid-Modifying Therapy (LMT)
- Where
- 320 sites in United States, Argentina and 25 more
- Volunteers
- 2,341 people
- Sponsor
- Sanofi